Affinity DataKi: 1.40nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 2.10nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 2.70nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 2.80nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 3.90nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4.20nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4.20nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4.20nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 4.30nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 6.30nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 8.20nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 9.40nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 9.5nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 10nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 12nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 14nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 23nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 35nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 39nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 81nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 86nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 175nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataKi: 285nMAssay Description:Inhibition of AlexaFluor647-tagged cyclic peptide binding to avi-tagged-biotinylated human PCSK9 measured after 2 hrs by Lance Streptavidin Europium ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.75nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of human DGAT2 expressed in Sf9 cell membranes assessed as triolein formation by LC/MS/MS analysis using oleoyl-CoA as substrateMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of human DGAT2 expressed in Sf9 cell membranes assessed as triolein formation by LC/MS/MS analysis using oleoyl-CoA as substrateMore data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of human DGAT2 expressed in Sf9 cell membranes assessed as triolein formation by LC/MS/MS analysis using oleoyl-CoA as substrateMore data for this Ligand-Target Pair
Affinity DataIC50: 11.9nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
Affinity DataIC50: 15.9nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
Affinity DataIC50: 16.7nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
TargetAlpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase(Homo sapiens (Human))
Merck
Curated by ChEMBL
Merck
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of MGAT2 (unknown origin) by CPM assayMore data for this Ligand-Target Pair
Affinity DataIC50: 32.9nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
Affinity DataIC50: 41.4nMpH: 7.0 T: 2°CAssay Description:DGAT2 activity was determined by measuring the amount of enzymatic product triolein (1,2,3-Tri(cis-9-octadecenoyl)glycerol) using the membrane prep m...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
TargetProprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair